Big pharma continues to invest heavily into molecular glue degraders. The latest deal has Eisai Co. Ltd. striking up a research collaboration that could bring Seed Therapeutics Inc. up to $1.5 billion in up-front and milestone payments. The two said they plan to discover, develop and commercialize MGDs for several undisclosed neurodegeneration and oncology targets.
Pinetree Therapeutics Inc. has entered into an exclusive option and global license agreement with Astrazeneca plc for a preclinical epidermal growth factor receptor (EGFR) degrader candidate.
Monte Rosa Therapeutics Inc. has submitted an IND application to the FDA for MRT-6160, a highly selective and orally bioavailable molecular glue degrader directed against VAV1 in development for systemic and neurological autoimmune diseases.
Sibylla Biotech SpA and the University of Texas MD Anderson Cancer Center have signed a strategic collaboration agreement to discover and develop novel small molecule folding interfering degraders (FIDs) for the treatment of cancer.
Scientists at the Institute of Cancer Research have generated a proteolysis targeting chimera (PROTAC) that successfully destroyed RIPK1 in cancer cells.
Amphista Therapeutics Ltd. has unveiled a new mechanism of action for the degradation of the emerging oncology target BRD9 that is differentiated from cereblon- or VHL-based PROTACs.
Degron Therapeutics Inc. has entered into a collaboration and exclusive license agreement with Takeda Pharmaceutical Co. Ltd. to discover and develop novel molecular glue degraders for multiple targets in oncology, neuroscience and inflammation.
Neosphere Biotechnologies GmbH has entered into a collaboration with Kymera Therapeutics Inc. that seeks to unlock undrugged or poorly drugged disease-causing protein targets that can be addressed by targeted protein degradation.
RSS
